NVO - Novo Nordisk's Semaglutide's Multi-Beneficial Effects: Weight Loss Improved Metabolic Markers Liver Fat Reduction in HIV-Related Liver Disease | Benzinga
The weekly injection of semaglutide has proven to be both safe and effective, reducing liver fat in individuals with HIV and fatty liver disease, as unveiled by data from a mid-stage study sponsored by the National Institutes of Health.
Semaglutide is the key ingredient in Novo Nordisk A/S’s (NYSE:NVO) popular drugs, including Wegovy for weight loss and Ozempic for diabetes.
Tuesday, Novo Nordisk’s FLOW kidney outcomes trial demonstrated a statistically significant and superior reduction in kidney disease progression and cardiovascular and kidney death of 24% for people treated with semaglutide 1.0 mg compared to placebo.